Lineage Cell Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

LCTX$1.08+5.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Shareholders' Equity

Three Months Ended September 30, 2024
Accumulated
Other · Total
Common Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’
	Shares	Amount	Deficit	Deficit	Income / (Loss)	Equity
BALANCE - June 30, 2024	188,824	$467,928	$(397,158)	$(1,425)	$(2,470)	$66,875
Shares issued upon exercise of stock options	13	10	—	—	—	10
Stock-based compensation	—	1,330	—	—	—	1,330
Unrealized gain on marketable debt securities	—	—	—	—	12	12
Foreign currency translation adjustment	—	—	—	—	(432)	(432)
Net loss	—	—	(3,034)	33	—	(3,001)
BALANCE - September 30, 2024	188,837	$469,268	$(400,192)	$(1,392)	$(2,890)	$64,794

Three Months Ended September 30, 2023
Accumulated
Other · Total
Common Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’
	Shares	Amount	Deficit	Deficit	Income / (Loss)	Equity
BALANCE - June 30, 2023	174,439	$448,249	$(372,971)	$(1,409)	$(2,611)	$71,258
Shares issued through ATM	538	784	—	—	—	784
Financing related fees	—	(28)	—	—	—	(28)
Shares issued upon exercise of stock options	10	8	—	—	—	8
Stock-based compensation	—	1,269	—	—	—	1,269
Unrealized gain on marketable debt securities	—	—	—	—	9	9
Foreign currency translation adjustment	—	—	—	—	518	518
Net loss	—	—	(7,110)	(48)	—	(7,158)
BALANCE - September 30, 2023	174,987	$450,282	$(380,081)	$(1,457)	$(2,084)	$66,660

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (CONTINUED)

Nine Months Ended September 30, 2024
Accumulated
Other · Total
Common Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’
	Shares	Amount	Deficit	Deficit	Income / (Loss)	Equity
BALANCE - December 31, 2023	174,987	$451,343	$(384,856)	$(1,396)	$(3,068)	$62,023
Shares issued through registered direct financing	13,462	14,000	—	—	—	14,000
Shares issued through ATM	56	70	—	—	—	70
Financing related fees	—	(113)	—	—	—	(113)
Shares issued upon vesting of restricted stock units, net of shares retired to pay employees’ taxes	45	(23)	—	—	—	(23)
Shares issued upon exercise of stock options	287	229	—	—	—	229
Stock-based compensation	—	3,762	—	—	—	3,762
Unrealized gain on marketable debt securities	—	—	—	—	5	5
Foreign currency translation adjustment	—	—	—	—	173	173
Net loss	—	—	(15,336)	4	—	(15,332)
BALANCE - September 30, 2024	188,837	$469,268	$(400,192)	$(1,392)	$(2,890)	$64,794

Nine Months Ended September 30, 2023
Accumulated
Other · Total
Common Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’
	Shares	Amount	Deficit	Deficit	Income / (Loss)	Equity
BALANCE - December 31, 2022	170,093	$440,280	$(363,370)	$(1,403)	$(3,571)	$71,936
Shares issued through ATM	4,775	6,625	—	—	—	6,625
Financing related fees	—	(221)	—	—	—	(221)
Shares issued upon vesting of restricted stock units, net of shares retired to pay employees’ taxes	53	(37)	—	—	—	(37)
Shares issued upon exercise of stock options	66	55	—	—	—	55
Stock-based compensation	—	3,580	—	—	—	3,580
Unrealized gain on marketable debt securities	—	—	—	—	150	150
Foreign currency translation adjustment	—	—	—	—	1,337	1,337
Net loss	—	—	(16,711)	(54)	—	(16,765)
BALANCE - September 30, 2023	174,987	$450,282	$(380,081)	$(1,457)	$(2,084)	$66,660

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.